Retinal Disease

Eyevensys, a Paris-based biotechnology company, has closed a round of $30 million in Series B financing intended for development of EYS606 for the treatment of chronic noninfectious uveitis, according to a press release.

NEPTUNE, N.J. – ERG was shown to detect retinal ischemia before the presence of retinopathy, unveiling retinal function changes that may not be present on funduscopy, according to Ashley Allee, OD, here at a New Jersey Academy of Optometry continuing education event.

QR-1123, a first-in-class investigational antisense oligonucleotide for the treatment of vision loss associated with autosomal dominant retinitis pigmentosa, received an orphan drug designation from the FDA, ProQR announced in a press release.

NEW YORK — At OSN New York 2019, Darius Moshfeghi, MD, discusses the progress being made around the world in research into artificial intelligence, deep learning and big data in the areas of diabetic and pediatric eye disease, among other areas of medicine.

Sepofarsen has received rare pediatric disease designation from the FDA for the treatment of Leber’s congenital amaurosis 10, according to a press release from ProQR Therapeutics.

SAN FRANCISCO — At the American Academy of Ophthalmology meeting, Daniela Ferrara, MD, MSc, PhD, senior medical director for Genentech/Roche, discusses the company’s ophthalmology personalized health care program intended to improve outcomes for patients with retinal diseases.

The Asia-Pacific Academy of Ophthalmology is pleased to welcome the Brunei Ophthalmology Society as the newest associate national member of APAO.

Severe retinal pigment epithelial damage after long-term drug cessation in patients with hydroxychloroquine retinopathy may lead to injury that chronically destabilizes cellular function, according to findings published in Retina.

Patients are at a higher risk of developing retinal vein occlusion if they have high-density lipoprotein cholesterol, according to a study conducted in the Department of Ophthalmology at Samsung Medical Center in Seoul, South Korea.

The Future is Now: Leaders in Ocular Gene Therapy meeting will be held for the first time Wednesday, Oct. 9, preceding the American Academy of Ophthalmology meeting in San Francisco.